
Lifeloc Reports Third Quarter 2026 Results
Monday, 16 November 2026 09:14 AM
Earnings
WHEAT RIDGE, CO / ACCESS Newswire / November 16, 2026 / Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2026.
Third Quarter Financial Highlights
Lifeloc posted quarterly net revenue of $2.522 million in the third quarter of 2026, resulting in a quarterly net loss of $(85) thousand, or $(0.03) per diluted share. These results compare to net revenue of $2.257 million and quarterly net loss of $(263) thousand, or $(0.10) per diluted share in the third quarter of 2025. Revenue for the quarter grew 12% versus the third quarter last year. For the first nine months of 2026, net revenue was $7.261 million and net loss was $(372) thousand, or $(0.14) per diluted share, compared with net revenue of $6.754 million and net loss of $(950) thousand, or $(0.35) per diluted share, for the same period in 2025. Total gross margin in the third quarter rose to 43% versus 40% for the same quarter last year. For the first nine months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $506 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss.
Alcohol Detection Products
We believe our core alcohol detection product lineup is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by addressing previously unmet market needs such as smartphone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.
SpinDetect™ Analyzer Platform
We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer - sometimes referred to as "Lab on a Disk" - is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) - the definitive laboratory standard - using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.
We have completed the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. We will be initiating beta testing of the oral-fluid analyzer focused on delta-9-THC detection using a prototype reader, with final component optimization underway, under a signed beta-testing agreement. The full commercial product is expected to measure delta-9-THC, followed by a multi-drug panel release. We previously anticipated a limited commercial launch of SpinDetect in Q1 of 2027; we now expect the limited commercial launch to occur in Q4 of 2027. In recent periods we devoted a substantial portion of our engineering and development resources to SpinDetect and, as a result, deferred upgrades and enhancements to our core breath alcohol testing products. We are redirecting a portion of those resources to our core products in the near term and will be conducting beta testing and the validation of SpinDetect with our current staff rather than with additional personnel. The upgrades to our core products will allow us to enter additional markets and generate incremental revenue, which we expect will help fund the work required to complete and bring SpinDetect to market.
Following the limited commercial launch, we plan to expand into additional drug panels and sample types, including blood and breath - the latter integrated with our LX9 breathalyzer. The SpinDetect™ reader is designed to accept multiple disk formats, which may also enable future applications beyond drug testing, such as detection of food-safety markers and environmental contaminants; these applications would require additional research, regulatory clearances, and potential expansion of our existing license rights. Our revised timeline and continued progress toward commercialization depend on our ability to generate the anticipated incremental revenue from our core products and on timely access to capital to support fabrication, validation, regulatory preparation, and market introduction. There can be no assurance that the launch will occur when currently expected.
"We are raising the priority of our alcohol testing research and development projects that can have a quick, positive impact on cash flow. While we had deferred some core business opportunities, transformational AI tools have reduced the cost and timeline for hardware and firmware upgrades, raising the return on investment for these projects," commented Dr. Wayne Willkomm, President and CEO. "Using advances in our core products to fund the big growth opportunity of the SpinDetect™ Centrifugal Drug Analyzer is consistent with our desire to fund from operations as best as we can."
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTCID:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our website, www.lifeloc.com/investor.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.
Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.
SpinDetect™ is a trademark of Lifeloc Technologies, Inc.
LIFELOC TECHNOLOGIES, INC. | |||||||
ASSETS | |||||||
CURRENT ASSETS: | September 30, 2026 (Unaudited) | December 31, 2025 | |||||
Cash and cash equivalents | $ | 930,539 | $ | 746,001 | |||
Accounts receivable, net | 785,442 | 772,380 | |||||
Inventories, net | 2,678,034 | 2,633,614 | |||||
Federal and state income taxes receivable | 55,381 | 55,981 | |||||
Prepaid expenses and other | 96,747 | 60,825 | |||||
Total current assets | 4,546,143 | 4,268,801 | |||||
PROPERTY, PLANT AND EQUIPMENT: | |||||||
Land | 317,932 | 317,932 | |||||
Building | 1,928,795 | 1,928,795 | |||||
Real-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | |||||
Production equipment, software and space modifications | 1,366,539 | 1,366,539 | |||||
Office equipment, software and space modifications | 197,686 | 197,686 | |||||
Sales and marketing equipment and space modifications | 230,543 | 225,173 | |||||
Research and development equipment, software and space modifications | 1,444,531 | 1,213,195 | |||||
Research and development equipment, software and space modifications not in service | - | 19,595 | |||||
Less accumulated depreciation | (3,745,873 | ) | (3,538,455 | ) | |||
Total property and equipment, net | 2,309,601 | 2,299,908 | |||||
OTHER ASSETS: | |||||||
Patents, net | 65,324 | 71,039 | |||||
Deposits and other | 81,560 | 46,820 | |||||
Total other assets | 146,884 | 117,859 | |||||
Total assets | $ | 7,002,628 | $ | 6,686,568 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable | $ | 543,342 | $ | 301,627 | ||||
Term loans payable, current portion | 56,123 | 54,850 | ||||||
Term loans payable (related party), current portion | 59,396 | - | ||||||
Subordinated debentures payable, current portion | 36,897 | 33,371 | ||||||
Customer and tenant deposits | 2,689 | 25,694 | ||||||
Accrued expenses | 344,565 | 321,112 | ||||||
Deferred revenue, current portion | 60,959 | 53,716 | ||||||
Product warranty reserve | 46,500 | 46,500 | ||||||
Total current liabilities | 1,150,471 | 836,870 | ||||||
TERM LOANS PAYABLE, net of current portion and | ||||||||
debt issuance costs | 1,016,171 | 1,058,426 | ||||||
TERM LOAN PAYABLE (Related Party), net current portion and | ||||||||
debt issuance costs | 440,604 | - | ||||||
SUBORDINATED DEBENTURES PAYABLE, net of current | ||||||||
portion and debt issuance costs | 653,219 | 681,343 | ||||||
DEFERRED REVENUE, net of current portion | 10,359 | 6,151 | ||||||
Total liabilities | 3,270,824 | 2,582,790 | ||||||
COMMITMENTS AND CONTINGENCIES (Note 6) | ||||||||
STOCKHOLDERS' EQUITY: | ||||||||
Common stock, no par value; 50,000,000 shares authorized, 2,752,616 | ||||||||
shares outstanding | 5,934,314 | 5,934,314 | ||||||
Retained earnings | (2,202,510 | ) | (1,830,536 | ) | ||||
Total stockholders' equity | 3,731,804 | 4,103,778 | ||||||
Total liabilities and stockholders' equity | $ | 7,002,628 | $ | 6,686,568 | ||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
| Three Months Ended September 30, | ||||||||
REVENUES: | 2026 | 2025 | ||||||
Product sales | $ | 2,512,530 | $ | 2,241,331 | ||||
Royalties | 9,344 | 16,117 | ||||||
Total | 2,521,874 | 2,257,448 | ||||||
COST OF SALES | 1,431,792 | 1,350,755 | ||||||
GROSS PROFIT | 1,090,082 | 906,693 | ||||||
OPERATING EXPENSES: | ||||||||
Research, development, and sustaining engineering | 505,982 | 458,747 | ||||||
Sales and marketing | 314,948 | 341,567 | ||||||
General and administrative | 319,223 | 340,705 | ||||||
Total | 1,140,153 | 1,141,019 | ||||||
OPERATING (LOSS) | (50,071 | ) | (234,326 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 8,734 | 7,840 | ||||||
Interest expense | (43,594 | ) | (36,953 | ) | ||||
Total | (34,860 | ) | (29,113 | ) | ||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (84,931 | ) | (263,439 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | - | - | ||||||
NET (LOSS) | $ | (84,931 | ) | $ | (263,439 | ) | ||
NET (LOSS) PER SHARE, BASIC | $ | (0.03 | ) | $ | (0.10 | ) | ||
NET (LOSS) PER SHARE, DILUTED | $ | (0.03 | ) | $ | (0.10 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,752,616 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,752,616 | ||||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
| Nine Months Ended September 30, | ||||||||
REVENUES: | 2026 | 2025 | ||||||
Product sales | $ | 7,236,986 | $ | 6,695,638 | ||||
Royalties | 23,657 | 41,588 | ||||||
Rental income | - | 16,632 | ||||||
Total | 7,260,643 | 6,753,858 | ||||||
COST OF SALES | 4,090,961 | 4,014,000 | ||||||
GROSS PROFIT | 3,169,682 | 2,739,858 | ||||||
OPERATING EXPENSES: | ||||||||
Research, development, and sustaining engineering | 1,480,708 | 1,551,689 | ||||||
Sales and marketing | 949,145 | 1,015,651 | ||||||
General and administrative | 1,021,478 | 1,065,657 | ||||||
Total | 3,451,331 | 3,632,997 | ||||||
OPERATING (LOSS) | (281,649 | ) | (893,139 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 24,121 | 31,128 | ||||||
Interest expense | (114,446 | ) | (87,753 | ) | ||||
Total | (90,325 | ) | (56,625 | ) | ||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (371,974 | ) | (949,764 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | - | - | ||||||
NET (LOSS) | $ | (371,974 | ) | $ | (949,764 | ) | ||
NET (LOSS) PER SHARE, BASIC | $ | (0.14 | ) | $ | (0.35 | ) | ||
NET (LOSS) PER SHARE, DILUTED | $ | (0.14 | ) | $ | (0.35 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,733,490 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,733,490 | ||||||
Lifeloc Technologies, Inc. | |||||||||||||||
| 2026 | |||||||||||||||
| Common Stock Shares | Common Stock Amount | Retained Earnings (Accumulated Deficit) | Total | ||||||||||||
Beginning balance, December 31, 2025 | 2,752,616 | $ | 5,934,314 | $ | (1,830,536 | ) | $ | 4,103,778 | |||||||
Net (loss) | - | - | (152,713 | ) | (152,713 | ) | |||||||||
Ending balance, March 31, 2026 | 2,752,616 | 5,934,314 | (1,983,249 | ) | 3,951,065 | ||||||||||
Net (loss) | - | - | (134,330 | ) | (134,330 | ) | |||||||||
Ending balance, June 30, 2026 | 2,752,616 | 5,934,314 | (2,117,579 | ) | 3,816,735 | ||||||||||
Net (loss) | - | - | (84,931 | ) | (84,931 | ) | |||||||||
Ending balance, September 30, 2026 | 2,752,616 | $ | 5,934,314 | $ | (2,202,510 | ) | $ | 3,731,804 | |||||||
| 2025 | ||||||||||||||||
| Common Stock Shares | Common Stock Amount | Retained Earnings (Accumulated Deficit) | Total | |||||||||||||
Beginning balance, December 31, 2024 | 2,664,116 | $ | 5,586,014 | $ | 639,863 | $ | 6,225,877 | |||||||||
Issuance of shares from option exercise | 88,500 | 336,300 | - | 336,300 | ||||||||||||
Warrants issued with subordinated debenture | - | 12,000 | - | 12,000 | ||||||||||||
Net (loss) | - | - | (292,686 | ) | (292,686 | ) | ||||||||||
Ending balance, March 31, 2025 | 2,752,616 | 5,934,314 | 347,177 | 6,281,491 | ||||||||||||
Net (loss) | - | - | (393,639 | ) | (393,639 | ) | ||||||||||
Ending balance, June 30, 2025 | 2,752,616 | 5,934,314 | (46,462 | ) | 5,887,852 | |||||||||||
Net (loss) | - | - | (263,439 | ) | (263,439 | ) | ||||||||||
Ending balance, September 30, 2025 | 2,752,616 | $ | 5,934,314 | $ | (309,901 | ) | $ | 5,624,413 | ||||||||
LIFELOC TECHNOLOGIES, INC. | ||||||||
| Nine Months Ended September 30, | ||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | 2026 | 2025 | ||||||
Net (loss) | $ | (371,974 | ) | $ | (949,764 | ) | ||
Adjustments to reconcile net income (loss) to net cash | ||||||||
(used in) operating activities- | ||||||||
Provision for doubtful accounts, net change | - | 1,500 | ||||||
Depreciation and amortization | 213,133 | 325,095 | ||||||
Amortization of debt issuance costs | 18,153 | 11,937 | ||||||
Changes in operating assets and liabilities- | ||||||||
Accounts receivable | (13,062 | ) | (133,415 | ) | ||||
Inventories | (44,420 | ) | 134,239 | |||||
Federal and state income taxes receivable | 600 | 24,729 | ||||||
Prepaid expenses and other | (35,922 | ) | (102,583 | ) | ||||
Deposits and other | (34,740 | ) | (34,559 | ) | ||||
Accounts payable | 241,715 | 133,342 | ||||||
Customer and tenant deposits | (23,005 | ) | (25,885 | ) | ||||
Accrued expenses | 23,453 | 34,753 | ||||||
Deferred revenue | 11,451 | 2,174 | ||||||
Net cash provided from (used in) operating | ||||||||
activities | 14,618 | (578,437 | ) | |||||
CASH FLOWS (USED IN) INVESTING ACTIVITIES: | ||||||||
Purchases of sales and marketing equipment | (5,370 | ) | (39,510 | ) | ||||
Purchases of research and development equipment, software and | ||||||||
space modifications | (211,741 | ) | (310,646 | ) | ||||
Net cash (used in) investing activities | (217,111 | ) | (350,156 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Principal payments made on term loan | (42,592 | ) | (41,356 | ) | ||||
Proceeds from issuance of subordinated debenture | - | 75,000 | ||||||
Proceeds from issuance of term loan | 500,000 | - | ||||||
Principal payments made on subordinated debentures | (41,141 | ) | - | |||||
Proceeds from issuance of shares from option exercise | - | 336,300 | ||||||
Net cash provided from financing | ||||||||
activities | 416,267 | 369,944 | ||||||
NET INCREASE (DECREASE) IN CASH | 184,538 | (558,649 | ) | |||||
CASH, BEGINNING OF PERIOD | 746,001 | 1,243,746 | ||||||
CASH, END OF PERIOD | $ | 930,539 | $ | 685,097 | ||||
SUPPLEMENTAL INFORMATION: | ||||||||
Cash paid for interest | $ | 96,292 | $ | 75,816 | ||||
Income tax refund received | $ | - | $ | 24,729 | ||||
Non-cash financing and investing activities: warrants issued with | ||||||||
subordinated debenture | $ | - | $ | 12,000 | ||||
Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
SOURCE: Lifeloc Technologies, Inc.
